Please provide your email address to receive an email when new articles are posted on . Researchers found significantly reduced odds for hypertension and diabetes among those with bronchiectasis vs.

Men and women with chronic obstructive pulmonary disease (COPD), bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease report differences in symptoms, mental health, disease burden, and ...

Results of a large, global clinical trial spanning five continents with over 1,700 patients with bronchiectasis, published this April in the New England Journal of Medicine, demonstrated benefits of ...

Queen's University Belfast-led research reports on a multicenter trial finding no significant reduction in pulmonary exacerbations with hypertonic saline or carbocisteine over 52 weeks among adults ...

Please provide your email address to receive an email when new articles are posted on . Diagnosis-related anxiety, depression or fear was reported by a larger proportion of women vs. men. After being ...

Insmed plans to file a New Drug Application with the Food and Drug Administration in the fourth quarter of 2024. Treatment with brensocatib reduced the frequency of pulmonary exacerbations in patients ...

A pulmonary specialist shares his approach to treating patients with bronchiectasis, highlighting gaps in knowledge that impact management practices. What are the current gaps in knowledge regarding ...

The ASPEN randomized trial showed that novel brensocatib cut the annualized rate of pulmonary exacerbations by around 20% compared with placebo. Brensocatib is a DPP-1 inhibitor that works by reducing ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration has approved Insmed's daily pill brensocatib, which will be sold under the brand name ...

New research underscores how air pollution and temperature extremes amplify risks for bronchiectasis patients, pointing to critical measures for safeguarding vulnerable groups. Study: Association of ...